Literature DB >> 16431855

A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia.

Robert van Seventer1, Alesia Sadosky, Melanie Lucero, Ellen Dukes.   

Abstract

BACKGROUND: Postherpetic neuralgia (PHN) develops in 8-24% of patients with herpes zoster. Few studies have evaluated the patient burden and treatment of PHN in general practice.
OBJECTIVES: To determine the patient burden of PHN with respect to pain intensity and impact on patient functioning and to characterise treatment patterns and health resource utilisation in general practice.
METHODS: Eighty-four patients with PHN were identified in general practice settings during an observational survey of neuropathic pain syndromes in six European countries. Patients answered a questionnaire that included: pain severity and interference items from the modified short form brief pain inventory (mBPI-SF); EuroQol (EQ-5D) survey; and questions related to current treatment, health status and resource utilisation. Physicians provided information on medications prescribed for PHN and pain-related co-morbidities (anxiety, depression and sleep disturbance).
RESULTS: Mean patient age was 71.0 +/- 12.8 years, 76% were > or = 65 years and 45% of patients had PHN > or = 1 year. The mean pain severity index was 4.2, reflecting moderate pain despite 89% of patients taking prescription medications for PHN. Few medications with demonstrated efficacy against PHN (e.g. carbamazepine and gabapentin) were prescribed, often at suboptimal doses. Pain severity was associated with reduced EQ-5D health state valuation (P<0.001), greater pain interference on all domains (P<0.001) and increased health resource utilisation (P = 0.008).
CONCLUSIONS: PHN causes substantial patient burden expressed as interference with daily functioning and reduced health status associated with pain severity. This burden may result in part from suboptimal management strategies and suggests a need for more effective pain management.

Entities:  

Mesh:

Year:  2006        PMID: 16431855     DOI: 10.1093/ageing/afj048

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  36 in total

1.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.

Authors:  Mélanie Drolet; Marc Brisson; Kenneth E Schmader; Myron J Levin; Robert Johnson; Michael N Oxman; David Patrick; Caty Blanchette; James A Mansi
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

2.  Chronic Orofacial Pain: Burning Mouth Syndrome and Other Neuropathic Disorders.

Authors:  Raymond C Tait; McKenzie Ferguson; Christopher M Herndon
Journal:  J Pain Manag Med       Date:  2017-01-30

3.  Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.

Authors:  Robert Arnou; Anne Fiquet; Stéphane Thomas; Christine Sadorge
Journal:  Hum Vaccin       Date:  2011-10-01

4.  5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia: results of a compassionate use programme in France.

Authors:  Florentin Clère; Claire Delorme-Morin; Brigitte George; Malou Navez; Bruno Rioult; Florence Tiberghien-Chatelain; Hervé Ganry
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

5.  Community and patient values for preventing herpes zoster.

Authors:  Tracy A Lieu; Ismael Ortega-Sanchez; G Thomas Ray; Donna Rusinak; W Katherine Yih; Peter W Choo; Irene Shui; Ken Kleinman; Rafael Harpaz; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey.

Authors:  Thomas Weinke; Alexander Edte; Sonja Schmitt; Kati Lukas
Journal:  Z Gesundh Wiss       Date:  2010-03-21

7.  The Economic Value of Vaccination: Why Prevention is Wealth.

Authors: 
Journal:  J Mark Access Health Policy       Date:  2015-08-12

8.  Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.

Authors:  Mark Ritchie; Hiltrud Liedgens; Mark Nuijten
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

9.  Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis.

Authors:  Antoni Sicras; Javier Rejas; Ruth Navarro; Albert Planas
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

10.  Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings.

Authors:  María Teresa Saldaña; Ana Navarro; Concepción Pérez; Xavier Masramón; Javier Rejas
Journal:  Rheumatol Int       Date:  2009-10-02       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.